503 results about "Cardiac functioning" patented technology

The systems, devices, and methods presented herein use a blood pump to obtain measurements of cardiac function. The system can quantify the functioning of the native heart by measuring certain parameters / signals such as aortic pressure or motor current, then calculate and display one or more cardiac parameters and heart function parameters, such as left ventricular pressure, left ventricular end diastolic pressure, or cardiac power output. These parameters provide valuable information to a user regarding current cardiac function, as well as positioning and function of the blood pump. In some embodiments, the system can act as a diagnostic and therapeutic tool. Providing cardiac parameters in real-time, along with warnings about adverse effects and recommendations to support cardiac function, such as increasing or decreasing the volumetric flow rate of blood pumped by the device, administering pharmaceutical therapies, and / or repositioning the blood pump allow clinicians to better support and treat cardiovascular disease.

The invention discloses application of an AXL inhibitor in preparation of a medicine for treating heart failure, and relates to the field of pharmacy. The invention provides application of an AXL inhibitor in a medicine for treating heart failure. The AXL inhibitor can remarkably inhibit abnormal activation of fibroblasts and can remarkably improve the heart function of a mouse with heart failure.

An electrocardiogram anomaly monitoring method and apparatus, a computer device and a storage medium. The method comprises: (S210) acquiring PPG data of a user; (S220) inputting the PPG data into a pre-trained ECG anomaly monitoring model, so as to obtain an output value of the ECG anomaly monitoring model; wherein the ECG anomaly monitoring model is pre-trained for, on the basis of the input PPG data, outputting an output value indicating whether ECG data corresponding to the input PPG data is estimated to have a cardiac function anomaly; (S230) and when the output value of the ECG anomaly monitoring model indicates that the ECG data of the user is estimated to have a cardiac function anomaly, sending an alert to the user equipment associated with the user.

The invention provides a four-dimensional cardiac function imaging method and device based on a biological magnetic signal. The method comprises the following steps: acquiring a magnetocardiogram signal of a to-be-detected object and dynamic structure information of a target trunk part in a full cardiac cycle; wherein the target trunk part at least comprises double lungs, a trunk, a heart cavity of the trunk and a pericardium structure, and the dynamic structure information comprises a contour structure and a multi-frame dynamic image; performing spatial registration on the dynamic structure information and the sensor for acquiring the magnetocardiogram signal to obtain coordinates of the sensor in a coordinate system of the dynamic structure information; according to the dynamic structure information, the coordinate of the sensor and the magnetocardiogram signal, calculating and reconstructing cardiac electrical excitation activity to obtain a calculation and reconstruction result; and converting the calculation reconstruction result into a four-dimensional visual image. According to the method, heart magnetic imaging and heart movement are combined, on the basis of obtained dynamic structure information and heart magnetic signals, the characteristics of biological magnetic signals are fully utilized, and the signal processing technology is integrated through space registration, so that accurate reconstruction of four-dimensional representation of the heart and visual display of functional activities are realized; therefore, the obtained four-dimensional visual image can completely represent the dynamic electrophysiological activities of the whole heart (including epicardium, endocardium and intrawall tissues) in a cardiac cycle, and a technical scheme with different concepts is provided for non-invasive imaging of cardiac electrical excitation activities.

Transcatheter aortic valve prostheses for improving the cardiac function of a patient suffering from coronary artery disease. Transcatheter aortic valve prostheses include a valve component and a frame. The valve component includes valve leaflets and a skirt. The frame includes access cells that improve access to a patient's coronary arteries if further intervention is required and / or includes a window or conduction protection cell that is oriented to align with a portion of conduction system of the heart in situ to reduce conduction disturbances of the anatomy. Suture patterns for attaching a commissure to a commissure post of the frame, and for attaching a tissue bumper to the commissure post, are also described.

Coaptation assist device for repairing cardiac valves and associated systems and methods are disclosed herein. A coaptation assist device configured in accordance with embodiments of the present technology can include, for example, a fixation member configured to press against cardiac tissue proximate to a native valve annulus, and a stationary coaptation structure extending away from the fixation member. The coaptation structure can include an anterior surface configured to coapt with a first native leaflet during systole and a posterior surface configured to displace at least a portion of a second native leaflet. The device also includes at least one sensor configured to detect parameters associated with at least one of cardiac function and device functionality. The sensors can be pressure sensors configured to detect left atrial pressure and / or left ventricular pressure.

The invention discloses a convolutional neural network information processing method for heart function dynamic monitoring, and belongs to the technical field of medical detection and monitoring. Comprising the following steps that multi-mode electrocardiosignal data and current physiological state parameters of a patient are obtained, and initial configuration of the intelligent heart function monitoring device is obtained; determining the signal quality grade of each signal channel, and generating a dynamic filtering adjustment strategy of the multi-modal signal acquisition module; configuring a feature extraction strategy of a double-branch convolutional neural network module based on the signal features of the target analysis signal segment and the physiological state parameters; performing multi-scale time sequence feature extraction and frequency domain autonomic nerve regulation feature extraction on the target analysis signal segment by using a double-branch convolutional neural network module according to a feature extraction strategy; executing arrhythmia classification, heart rate variability parameter quantification, heart function evaluation grade and graded early warning tasks, and outputting multi-stage intelligent early warning information from normal monitoring, potential risk and abnormal early warning to an emergency state.

The invention discloses a multi-mode-based flexible wearable heart function monitoring method, system and device, and relates to the technical field of health monitoring, and the method comprises the steps: outputting a multi-mode signal through a flexible patch sensing module when the flexible patch sensing module is arranged in a detection area; wherein the flexible patch sensing module comprises an electrocardio sensor, a pulse wave sensor, a heart sound sensor, a strain sensor and a microfluidic biosensor. According to the invention, high-precision synchronous signal acquisition is realized through flexible patch integrated multi-modal sensing, heart multi-source signal features are adaptively extracted in combination with a multi-scale convolutional neural model, and timing sequence relevance is captured by using a bidirectional long-short-term memory network, so that the accuracy and reliability of heart disease diagnosis are remarkably improved, and the accuracy and reliability of heart disease diagnosis are improved. Meanwhile, non-invasive and continuous monitoring and early pathological screening are supported.

A wearable device for comprehensive bio-monitoring of physiologic metrics to determine metabolic, pulmonary and cardiac function and oxygen saturation measurements from breathing mask apparatuses. The device non-invasively monitors the physiologic profile of the subject, and is capable of detecting physiologic changes, predicting onset of symptoms, and alerting the wearer or another person or system. In some embodiments, the device comprises both a wearable sensor suite and a portable gas composition and flow analysis system. In preferred embodiments, it comprises a miniaturized non-invasive sensor suite for detecting physiologic changes to detect dangerous breathing or other health conditions. The acquired physiologic profile is used to generate alarms or warnings based on detectable physiological changes, to adjust gas delivery to the subject, alter mission profiles, or to transfer control of the craft or other duties away from a debilitated subject. The device is compact, portable, vehicle independent and non-encumbering to the subject.

The invention relates to application of an MYZAP overexpression vector in preparation of a medicine for preventing and treating MIRI, and belongs to the technical field of biological medicine. In order to solve the problem that application of gene drugs in prevention and treatment of myocardial ischemia reperfusion injury is limited, the invention provides application of an MYZAP gene overexpression recombinant vector in preparation of drugs for prevention and treatment of myocardial ischemia reperfusion injury, and the MYZAP gene overexpression recombinant vector is an adeno-associated virus vector AAV9-MYZAP for overexpressing MYZAP. Experiments prove that MYZAP overexpression can improve the cardiac function after myocardial ischemia reperfusion, reduce the occurrence rate of arrhythmia and improve the functions of sodium ion channels, potassium ion channels and calcium ion channels of myocardial cells. On the basis, the invention further provides a medicine for preventing and treating myocardial ischemia reperfusion injury, a new strategy is provided for gene therapy of myocardial ischemia reperfusion injury, and the medicine has a wide clinical application prospect.

The invention discloses an application of rilpivirine (RPV) in preparation of a medicine for treating myocardial infarction, and relates to the field of medicines for treating myocardial infarction. The invention belongs to the technical field of biological medicine. According to the present invention, the acute myocardial infarction (AMI) disease mouse model is constructed through the induction of the permanent ligation of the left anterior descending branch; after rilpivirine is orally taken, the conditions of survival, heart function, structure change and the like of the AMI mouse model during X weeks after operation are observed. Results show that rilpivirine (as shown in the formula I) has the effects of remarkably improving the cardiac function of AMI injury, relieving cardiac remodeling and increasing the survival rate of AMI mice. Therefore, a new technical means is provided for treatment of myocardial infarction, and rilpivirine has a wide application prospect in treatment of myocardial infarction diseases. # imgabs0 #

The invention provides application of a monascus composition in preparation of a medicine for preventing and / or treating coronary microcirculation disturbance. The monascus composition comprises one or more of cortex mori, ramulus mori and folium mori, monascus and radix puerariae. When the composition containing the red yeast rice is applied to preparation of the medicine for preventing and / or controlling coronary microcirculation disturbance, the abnormal microvascular structure can be improved (myocardial microvascular density MVD is increased, edema around microvessels is relieved, the lumen stenosis phenomenon is improved, and the endothelial cell condition is good); 2) microvascular occlusion is improved (pathologic results show that microvascular contents are reduced); (3) the abnormal vasodilatation and contraction function of the microvessels is improved (NO is increased); 4) improving blood lipid metabolism disorder; and (5) the heart function is improved (the left ventricular ejection fraction LVEF and the left ventricular short axis shortening rate LVFS are improved, and the left ventricular pressure maximum rising rate LV + dp / dtmax and the left ventricular pressure maximum falling rate LV-dp / dtmax are increased).

The invention relates to the field of medical image examination, and discloses a one-stop heart magnetic resonance examination technology which comprises the following steps: S1, high-integration-degree nuclear magnetic resonance scanning technology: acquiring original data of various heart magnetic resonance examinations through one-time scanning by adopting a high-integration-degree imaging sequence, the original data comprises images with different contrast ratios for measuring myocardial tissues T1, T2 and T2 * and film images for evaluating heart and ventricular functions; s2, expansion type deep learning reconstruction: reconstructing all different T1, T2 and T2 * weighted images and movie images in quantitative imaging and movie imaging data by adopting a reconstruction technology based on deep learning; and S3, quantitative image reconstruction: adopting a quantitative image reconstruction technology based on deep learning to reconstruct T1, T2 and T2 * quantitative images. According to the method, movie imaging for heart function examination and T1 quantitative imaging, T2 quantitative imaging and T2 * quantitative imaging for myocardial tissue characterization are completed in one-time scanning.

The systems, devices, and methods presented herein use a heart pump to obtain measurements of cardiovascular function. The heart pumps described herein can operate in parallel with and unload the heart. The system can quantify the functioning of the native heart by measuring certain parameters / signals such as pressure or motor current, then calculate and display one or more metrics of cardiovascular function. These metrics, such as left ventricular end diastolic pressure (LVEDP), left ventricular pressure, and contractility, provide valuable information to a user regarding a patient's state of heart function and recovery.

The invention relates to the technical field of medical imaging, and provides an automatic measurement method, system and equipment for the cardiac muscle full segment thickness of an echocardiogram, and the method comprises the steps: determining a sector rectangular frame in an ultrasonic video stream through employing a deep learning target detection model, so as to determine a cutting region; cutting the ultrasonic video stream based on the cutting area, and scaling the cut ultrasonic cardiac image to a target size in an equal proportion; performing feature extraction on the echocardiography image through a feature extraction module and generating a feature map; cardiac muscle segmentation is completed through the cardiac muscle segmentation module, and mitral valve endpoint recognition is completed through the mitral valve endpoint recognition module; based on the data obtained by the myocardial segmentation module and the mitral valve endpoint identification module, a post-processing module is adopted to calculate and visually output a myocardial full segment thickness result at the end of diastole or end of systole; the cardiac muscle full segment thickness can be effectively measured, the accuracy and repeatability of cardiac function parameter measurement can be improved, and the medical examination process is optimized.

The invention discloses a cardiac function rehabilitation state monitoring method for coronary heart disease postoperative population. The method comprises the following steps: constructing a third-order dynamic baseline adaptive to postoperative pathological evolution; carrying out stress-physiological coupling modeling on the basis of a double-AI (Artificial Intelligence) collaborative architecture; and carrying out trend early warning of equal-condition longitudinal pairing. The heart function rehabilitation state monitoring system comprises an electrocardiosignal preprocessing unit, the electrocardiosignal preprocessing unit is connected with a multi-dimensional electrocardiosignal feature extraction unit, and the multi-dimensional electrocardiosignal feature extraction unit is connected with a third-order individualized baseline management unit and a front stress recognition AI unit. And the third-order individualized baseline management unit and the front stress identification AI unit are respectively connected with the core correlation deduction AI unit. According to the method and system for monitoring the cardiac function rehabilitation state of the crowd after the coronary heart disease operation, dynamic baseline construction and the pathological evolution rule after the coronary heart disease operation are deeply bound, and the problem of high false alarm of a traditional fixed baseline in the early stage of the operation is thoroughly solved through triple-stage design and a dual calibration mechanism.

A method for assisting a heart ventricle can comprise providing a longitudinally expandable member that is reversibly expandable along a longitudinal dimension, wherein the longitudinally expandable member can include adjacent abutting portions meeting at respective bends that form acute angles along the longitudinal dimension. The method can include securing a first end portion of the longitudinally expandable member to a first wall portion of the heart ventricle via a first anchor engagement feature associated with the first end portion. The method can include securing a second end portion of the longitudinally expandable member to a second wall portion of the heart ventricle via a second anchor engagement feature associated with the second end portion, the plurality of bends between the first and second end portions allowing augmenting expansion of the heart ventricle using spring force of the longitudinally expandable member to thereby improve heart function.

The invention belongs to the technical field of medicines, and mainly relates to application of 3 ', 4'-dihydroxy flavonol in treatment of hypertension. The invention firstly provides application of 3 ', 4'-dihydroxy flavonol or pharmaceutically acceptable salt thereof in preparation of products for preventing and / or treating hypertension. The invention also provides an application of the 3 ', 4'-dihydroxy flavonol or the pharmaceutically acceptable salt thereof in preparation of a product, and the product is used for reducing blood pressure; the blood vessel function reduction is improved; the blood vessel wall thickening is improved; the heart function reduction is improved; the 3 ', 4'-dihydroxy flavonol can improve any one or more of myocardial cell hypertrophy, and the invention further provides a product which comprises an effective dose of 3 ', 4'-dihydroxy flavonol or pharmaceutically acceptable salt thereof. The application finds that the 3 ', 4'-dihydroxy flavonol and the pharmaceutically acceptable salt thereof can be effectively used for preventing or treating hypertension, and a new way is opened up for the treatment of hypertension or hypertension-related diseases.

Systems and methods and devices are provided for treating conditions such as heart failure and / or pulmonary hypertension by at least partially occluding flow through the superior vena cava for an interval spanning multiple cardiac cycles. A catheter with an occlusion device is provided along with a controller that actuates a drive mechanism to provide at least partial occlusion of the patient's superior vena cava, which reduces cardiac filling pressures, and induces a favorable shift in the patient's Frank-Starling curve towards healthy heart functionality and improved cardiac performance. The occlusion device may include a lumen obstructed by a relief valve that may permit fluid flow through the occlusion device to release an excessive build-up of pressure.

The invention relates to the technical field of medical monitoring, in particular to an echocardiogram remote monitoring system for a heart failure patient, and the system comprises an echocardiogram device which is used for obtaining the personal information and echocardiogram of the heart failure patient; the data transmission subsystem is used for synchronizing the personal information and the echocardiography to a medical institution; the real-time monitoring subsystem is used for monitoring heart function parameters of the heart failure patient in real time; the data analysis subsystem is used for analyzing the echocardiogram and the cardiac function parameters to obtain a comprehensive analysis result; the abnormal early warning subsystem is used for identifying abnormal information in the comprehensive analysis result and performing early warning; and the cloud storage database is used for storing the personal information, the echocardiogram, the cardiac function parameters, the comprehensive analysis result and the abnormal information. According to the invention, the remote monitoring of the echocardiogram is realized, the medical resource configuration is optimized, and the medical convenience is enhanced.

The invention discloses a cardiac functional region modeling method based on a deep generative adversarial network. The method comprises the following steps: S1, collecting cardiac medical image data; s2, constructing a cardiac medical image data set; s3, constructing an improved deep generative adversarial network; s4, inputting the preprocessed cardiac medical image data into an improved deep generative adversarial network, and outputting a cardiac functional region segmentation prediction result by a generator of the improved deep generative adversarial network; s5, optimizing network parameters of the generator and the discriminator; and S6, performing reasoning calculation on the preprocessed cardiac medical image data, outputting a cardiac function region segmentation result, and performing post-processing on the cardiac function region segmentation result based on discrimination results of the global discriminator and the local discriminator to generate a final cardiac function region modeling result. According to the method, the segmentation precision of the heart function region, the consistency of cross-modal image segmentation and the reliability of a final segmentation result are remarkably improved.

The invention features methods for the treatment of a cardiovascular disease using a polypeptide containing an extracellular ActRII variant, such as an ActRIIA variant, ActRIIB variant, or ActRII chimera. The polypeptide may include an extracellular ActRII variant fused to an Fc domain monomer. Treatment of a cardiovascular disease with a polypeptide described herein may reduce fibrosis, reduce inflammation, reduce cardiac remodeling, improve cardiac function, improve ventricular function, or slow or inhibit disease progression, which may reduce or delay the need for coronary revascularization, heart valve repair or replacement, implantation of a cardioverter-defibrillator, cardiac resynchronization therapy, a ventricular assist device, or a heart transplant.

The invention discloses a construction method of a sepsis cardiomyopathy diagnosis model and a diagnosis system, and relates to the technical field of biomedicine, and the method comprises the following steps: carrying out multi-mode ultrasonic data dynamic collection and clinical data collection on a sepsis patient; according to the multi-mode ultrasonic data, evaluating the overall and local diastolic and contraction functions of the left ventricle and the right ventricle of the heart of the patient with sepsis cardiomyopathy, and performing preliminary diagnosis of sepsis cardiomyopathy in combination with clinical data; the method comprises the following steps: dividing multi-modal ultrasonic data of a sepsis patient into a training set and a verification set by using an Rcaret packet, and carrying out minimum absolute contraction and LASSO regression analysis on the training set to determine a preliminary prediction factor; carrying out logistic regression analysis on the preliminary prediction factor, and determining an independent prediction factor; the independent predictive factors are translated in nomoscore through an rms packet to obtain a column diagram, the independent predictive factors are visually presented according to the weights of the independent predictive factors, and the probability of occurrence of sepsis cardiomyopathy is measured. According to the invention, comprehensive and dynamic quantitative evaluation of the cardiac function of the patient is realized based on the multi-modal ultrasonic parameters.

Methods, systems, and devices for evaluating function of a heart are provided. The methods can include use of one or more imaging modalities to assess diastolic function. The methods, systems, and devices can employ various features of a cardiac volume curve to assess cardiac function. The methods, systems, and devices can be used to guide diagnosis, therapy, and / or training for sick or well patients. Methods, systems, and devices for assessing likelihood of hospital readmission for a heart failure patient are also provided.

The invention relates to application of piRNA-AB352916 and a mimetic thereof in preparation of a medicine for treating ischemic heart disease, and belongs to the technical field of medicines. In order to solve the problem that a medicine capable of promoting myocardial cell proliferation and inhibiting myocardial cell apoptosis is lacked in the treatment process of the ischemic heart disease, the invention provides application of piRNA-AB352916 and a mimetic thereof in preparation of a medicine for treating the ischemic heart disease. According to the application disclosed by the invention, the expression level of the piRNA-AB352916 in myocardial regeneration model tissues after cardiac apex resection is obviously increased, and animal experiments prove that the myocardial specific overexpression piRNA-AB352916 not only can promote myocardial cell proliferation, but also can inhibit myocardial cell apoptosis, so that the myocardial infarction area is reduced, and the cardiac function of an infarction mouse is improved. The invention proves that the piRNA-AB352916 and the analogue thereof have prevention and treatment values on the ischemic heart disease.

The invention relates to a non-invasive cardiac function evaluation system and method, and the system comprises an ultrasonic video collection module which is responsible for the collection of a cardiac image, and guarantees the collection of LVEDV and LVESV data. The preprocessing module locates a ventricle motion key time point, cuts a video and standardizes the image size. The feature extraction module extracts spatial and temporal features of the echocardiogram by using a C3D network. The multi-task learning network module optimizes heart function indexes such as EF, EDV and ESV through a shared feature extraction network and a task specific learning network, and controls the complexity of the model by applying L2 regularization. According to the non-invasive cardiac function evaluation system and method, space and time sequence characteristics of an echocardiography video are extracted through a C3D network with an attention mechanism; different weights are given to the sub-tasks, multi-task learning is carried out in a joint training mode, ejection fraction prediction is achieved, and doctors are assisted to carry out more accurate heart function evaluation.

Provided in the present application are a biomagnetic signal-based four-dimensional cardiac function imaging method and device. The method comprises: acquiring a cardiac magnetic signal of a subject to be tested and dynamic structure information of a target torso part within a full cardiac cycle, wherein the target torso part at least comprises two lungs, a torso, and a heart chamber and a pericardium structure thereof, and the dynamic structure information comprises a contour structure and a plurality of frames of dynamic images; performing spatial registration on the dynamic structure information and a sensor acquiring the cardiac magnetic signal to obtain coordinates of the sensor in a coordinate system of the dynamic structure information; calculating and reconstructing a cardiac electrical excitation activity based on the dynamic structure information, the coordinates of the sensor, and the cardiac magnetic signal to obtain a calculation and reconstruction result; and converting the calculation and reconstruction result into a four-dimensional visualization image.

A wearable medical device is provided for monitoring a cardiac condition of a patient, where the device is releasably mounted to the patient's chest and includes at least two skin-facing electrodes forming a first one or more ECG leads for ongoing monitoring of heart functioning and at least one touch electrode for intermittently obtaining additional circuit vectors for deriving additional metrics regarding the functioning of the patient's heart. Each touch electrode is configured to form an additional lead / vector that is a larger vector and / or separated by at least 15° from a corresponding first lead / vector formed from the first one or more ECG leads in a vector cardiogram representation of the first one or more ECG leads and the additional lead / vector.

An assessment of basal cardiac fitness uses noninvasively obtained physiological measures to determine the presence of a basal physiological state and cardiometric measures to determine cardiac fitness. In the presence of preload independence and cardiac vagal control, cardiometric signals are acquired that are sensitive to cardiac function and include information indicative of the opening and closing of the individual's aortic valve. The cardiometric signals are analyzed by a cardiac fitness assessment system for the determination of basal cardiac fitness. The invention assures preload independence through the assessment of observational physiological parameters or the use of physiological parameters obtained following alterations in venous return. The invention assures the presence of cardiac vagal control by assessment of measured parameters, including the presence of respiratory sinus arrhythmia. The resulting test is specific for cardiac function without dependencies on physical activities associated with heart rate elevation or respiratory capabilities.

Systems, devices and methods are provided for supporting cardiac function. A device comprises a catheter having a shaft with a distal end portion configured for advancing through an aortic valve to a left ventricle of a patient and an impeller coupled to the distal end portion of the catheter. One or more inlets are positioned distal of the impeller and coupled to an internal lumen within the catheter to draw blood from the left ventricle through the inlets and into the internal lumen. One or more outlets positioned proximal of the impeller and coupled to the internal lumen to pump the blood through the outlets and into the aorta. The device further includes an extracorporeal motor coupled to a proximal end portion of the catheter and a drive member extending through the catheter shaft and coupling the impeller with the motor to rotate the impeller. The motor may comprise a non-contact motor that generates a magnetic field to rotate the drive member.